David Wald

Sources

Sources are listed once and connected to each accepted claim they support. Excerpts preserve the source language used in the review.

1. [1]

   David Wald | Pathology | School of Medicine | Case Western Reserve University

   20 source claims · Reviewed Sep 9, 2026

   Show supporting evidence

   Biographical context: In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology.

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Biographical context: postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Degree: Bachelor of Science

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Degree: MD

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Degree: PhD

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Education record: Case Western Reserve University

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Education record: Clinical Pathology at University Hospitals Cleveland Medical Center

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Education record: David Wald graduated from Cornell University in 1997.

   David Wald graduated from Cornell University in 1997.

   Education record: Doctor of Medicine Case Western Reserve University Pathology 2005

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Education record: graduate student

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Education record: MSTP Student

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Education record: postdoctoral research

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Education record: ultimately attaining a Ph.D. in Pathology

   ultimately attaining a Ph.D. in Pathology

   Identity: David Wald

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Professional role: Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center

   Professional role: Physician, Department of Pathology, Clinical

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Professional role: Professor, Department of Pathology, School of Medicine

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Professor, Department of Pathology, School of Medicine

   Official profile: Official profile

   David Wald, MD, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor, Department of Pathology, School of Medicine Co-Leader, Immune Oncology Program, Case Comprehensive Cancer Center David Wald graduated from Cornell University in 1997. He then matriculated to Case Western Reserve University as an MSTP Student. While a graduate student, he studied Toll-like receptor signaling ultimately attaining a Ph.D. in Pathology. After the completion of his medical school requirements, Dr. Wald continued his clinical training in Clinical Pathology at University Hospitals Cleveland Medical Center. Dr. Wald also conducted postdoctoral research in the laboratories of Drs. Bryan Roth and William Tse. While in these laboratories, Dr. Wald developed an interest in cancer drug development and began to identify novel drug candidates for Acute Myeloid Leukemia and to explore their mechanisms of action. In 2008, Dr. Wald joined Case Western Reserve University's Department of Pathology. My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia. David Wald's Biography Research Information Research Projects Our research efforts are centered around the identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML). AML is one of the most common forms of leukemia in adults and despite advances in treatment the median survival in patients over the age of 56 is less than one year. One of the major problems is that elderly patients frequently are not able to tolerate the current therapeutics which have high toxicities leaving them with no satisfactory options. Our laboratory is involved in elucidating novel therapeutic approaches to more specifically target AML cells to try to improve the efficacy and lessen the toxicities of AML therapy. In particular, we are actively investigating three approaches that involve ATP depletion-mediated differentiation, the design of novel nucleoside analogues that exhibit leukemic cell preferential uptake, and the targeting of a particular kinase that appears to be dysregulated in AML. We are currently conducting studies to both define the mechanisms of these strategies as well as to further assess their clinical potential using both in vitro and mouse in vivo based approaches. External Appointments Title Physician, Department of Pathology, Clinical Organization/Publication University Hospitals Publications View All Publications Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., Tuohy, V. K., Fairchild, R. L., de la Motte, C., Cua, D., Vallance, B. A., Li, X. "The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.." Immunity. 2007 Apr;26(4):461-75. Epub 2007 Mar 29. Gregory, T. K., Wald, D., Chen, Y., Vermaat, J. M., Xiong, Y., Tse, W. "Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.." J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/[contact withheld]. Education Doctor of Medicine Case Western Reserve University Pathology 2005 Bachelor of Science Cornell University 1997 Residencies, Internships and Fellowships Clinical Pathology University Hospitals Case Medical Center Additional Information View External Profile

   Research interests: identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML)

   identification and development of novel therapeutic strategies for cancer with a particular focus on Acute myeloid leukemia (AML)

   Research interests: My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia.

   My area of investigation includes cellular therapies for cancer, cancer drug development, and genetic and molecular analyses of leukemia.